Drugs / Doxycycline
Doxycycline
also known as
doxycycline hyclate · doxycycline monohydrate · Doxycyclin · DOX · Oracea · Adoxa · Doxycycline Hcl · Nanodox · +22 more
Small molecule targets MMP2, MMP9 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | VIBRAMYCIN | — | 1992-12-15 | fda.gov ↗ |
| Approved | US (FDA) | VIBRAMYCIN | — | 1967-12-06 | fda.gov ↗ |
| Filed | EU (EMA) | D-PLEX₁₀₀ | surgical site infections | — | “PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month” polypid.com ↗ |
Trials 229 · started per year
today
US approved 1967
1
1
1
3
1
4
3
3
9
5
9
7
8
5
9
9
11
11
5
8
12
14
10
18
13
11
7
8
8
11
3
1967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
News releases announcing trial results or a regulatory action · 42
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | PolyPid Ltd. | Regulatory European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀ polypid.com ↗
today announced that the European Medicines Agency (“EMA”) has validated the Company’s recently submitted Marketing Authorization Application (“MAA”) for D-PLEX₁₀₀, its lead product candidate for the prevention of post abdominal surgery incisional infections. |
| 2026-06-01 | PolyPid Ltd. | Regulatory PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ polypid.com ↗
today announced the successful completion of its New Drug Application (“NDA”) submission on a rolling review basis to the U.S. Food and Drug Administration (“FDA”) for D-PLEX 100 |
| 2026-04-28 | PolyPid Ltd. | Results PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting polypid.com ↗
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery |
| 2026-04-13 | PolyPid Ltd. | Results PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 polypid.com ↗
Detectable doxycycline concentrations were observed for up to 763 hours (approximately 32 days), with no burst, following local application of D-PLEX₁₀₀ during surgery. |
| 2026-03-17 | PolyPid Ltd. | Regulatory PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application polypid.com ↗ |
| 2025-12-03 | PolyPid Ltd. | Regulatory PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission polypid.com ↗
The FDA agreed that the Company’s existing clinical data package, including results from the Phase 3 SHIELD II trial, appears adequate to support NDA submission and review. |
| 2025-10-24 | Journey Medical Corporation | Results Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference journeymedicalcorp.com ↗
DFD-29 demonstrated superior efficacy in IGA success rates and inflammatory lesion counts versus both placebo and doxycycline (P<0.001 for all comparisons) |
| 2025-09-30 | PolyPid Ltd. | Results PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress polypid.com ↗
The trial demonstrated that D-PLEX₁₀₀, when administered alongside standard of care, achieved a 38% reduction (p<0.005) in the combined endpoint of surgical site infections, reinterventions, or mortality compared to standard of care alone. |
| 2025-06-09 | PolyPid Ltd. | Results PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints polypid.com ↗
The trial successfully met all key secondary efficacy endpoints, including a 58% reduction in the rate of surgical site infections (“SSI”) in patients treated with D-PLEX 100 arm versus standard of care (“SoC”) arm (p<0.005). |
| 2024-10-21 | PolyPid Ltd. | Results PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery polypid.com ↗
For this reason, while the SHIELD I study did not achieve its primary endpoint, both pre-specified and post-hoc analyses suggested that D-PLEX 100 may benefit patients at increased risk of surgical site infections (SSIs), including those with lengthy incisions. |
| 2024-06-01 | Alembic Pharmaceuticals Ltd. | Regulatory 28th June, 2024, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Capsules, 40 mg. |
| 2024-03-15 | Lupin Limited | Regulatory Lupin Receives Approval from U.S. FDA for Doxycycline for Injection USP lupin.com ↗ |
| 2023-10-04 | PolyPid Ltd. | Results PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform polypid.com ↗
PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the publication of positive preclinical results demonstrating, for the first time, the safety profile of D-PLEX 100 and the PLEX technology platform in juvenile animals. |
| 2023-07-01 | Alembic Pharmaceuticals Ltd. | Regulatory APL-PR-USFDA-Products-Approval-Qtr-Ended-30062023.pdf alembicpharmaceuticals.com ↗ |
| 2023-06-29 | PolyPid Ltd. | Results PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections polypid.com ↗
The data showed the significant antibacterial activity of D-PLEX 100 in pre-clinical and phase 2 clinical studies against a wide range of bacteria tested, including resistant ones. |
| 2023-06-28 | Galderma R&D | Results WCD 2023: Galderma’s scientific presentations galderma.com ↗
Subantibiotic dose doxycycline is effective in rosacea independent of patient weight and disease severity |
| 2023-05-22 | PolyPid Ltd. | Regulatory PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections polypid.com ↗
PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the U.S. Food and Drug Administration (FDA) agreed to Company’s SHIELD II Phase 3 trial design evaluating D-PLEX 100 for the prevention of abdominal colorectal surgical site infections (SSIs). |
| 2023-01-24 | PolyPid Ltd. | Regulatory PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery polypid.com ↗
The FDA stated that the ongoing SHIELD II study, which to date has enrolled over 200 patients, could potentially serve as such a study. |
| 2023-01-03 | PolyPid Ltd. | Results PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery polypid.com ↗
D-PLEX 100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care |
| 2022-11-08 | Lupin Limited | Regulatory Lupin Receives Tentative Approval from U.S. FDA for Doxycycline Capsules lupin.com ↗
Mumbai, Baltimore, November 08, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Doxycycline Capsules, 40 mg, to market a generic equivalent of Oracea® Capsules, 40 mg, of Galderma Laboratories, L.P. |
| 2022-10-07 | Galderma R&D | Results Galderma study paves the way for an effective, new acne treatment combination galderma.com ↗
The Journal of Clinical and Aesthetic Dermatology recently published results from a Galderma-sponsored DUAL Phase 4 study demonstrating the effectiveness of a new treatment combination in improving quality of life for severe acne patients1. |
| 2022-09-28 | PolyPid Ltd. | Regulatory PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery polypid.com ↗
The centralized process eligibility is granted to D-PLEX 100 under the Therapeutic Innovation criteria which underscores that D-PLEX 100 provides a new alternative to patients in preventing post abdominal surgical site infections (SSIs). |
| 2022-09-19 | PolyPid Ltd. | Results PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery polypid.com ↗
today announced the peer-reviewed publication of positive clinical data from the previously completed Phase 2 study of D-PLEX 100 for the prevention of surgical site infections (SSIs) in abdominal surgery. |
| 2022-09-02 | PolyPid Ltd. | Results PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery polypid.com ↗
D-PLEX 100 + SoC Achieved a Statistically Significant Reduction of 54 percent on the Primary Endpoint versus SoC alone (p<0.0032) |
| 2022-04-25 | PolyPid Ltd. | Results PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine polypid.com ↗
Presentation evaluates the effect of D-PLEX 100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients |
| 2022-03-25 | Galderma R&D | Results Galderma to highlight latest science and innovation across its product portfolio at the 2022 AAD Annual meeting galderma.com ↗
DUAL Study: Trifarotene Plus Doxycycline Has Proven Efficacy and Safety in Severe Acne Vulgaris |
| 2021-05-19 | PolyPid Ltd. | Regulatory PolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX₁₀₀ Development Program polypid.com ↗
FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX 100 for the Prevention of Surgical Site Infections in Colorectal Surgery |
| 2020-11-24 | PolyPid Ltd. | Regulatory PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Colorectal Surgery polypid.com ↗
D-PLEX 100 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of surgical site infections (SSIs) in patients undergoing elective colorectal surgery. |
| 2020-08-03 | PolyPid Ltd. | Regulatory PolyPid Granted Fast Track Designation from FDA for D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery polypid.com ↗
PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that D-PLEX 100 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the prevention of post abdominal surgery incisional infections. |
| 2020-03-01 | Alembic Pharmaceuticals Ltd. | Regulatory 5th March, 2020, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Doxycycline Hyclate Tablets USP, 20 mg. |
| 2019-10-16 | PolyPid Ltd. | Results PolyPid Announces Positive Top-line Results from Phase 2 Clinical Trial of D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Surgery polypid.com ↗
In the Intent to Treat (ITT) population, the local administration of D-PLEX 100 resulted in a statistically significant decrease in SSIs of 57 percent, compared to SoC alone (p<0.0136). |
| 2019-05-21 | PolyPid Ltd. | Regulatory PolyPid Receives a Second QIDP Designation for D-PLEX100 in Abdominal Surgery polypid.com ↗
PolyPid Ltd., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, locally administered therapies, announced today that the United States Food and Drug Administration (FDA) has granted a second Qualified Infectious Disease Product (QIDP) designation to D-PLEX 100 for the prevention of post-abdominal surgery incisional infection. |
| 2019-03-01 | Galderma R&D | Results Galderma: New data reveals benefits of combining oral and topical treatment in patients with severe papulopustular rosacea galderma.com ↗
Today, Galderma shares the results of its ANSWER study, which highlights a superior reduction of inflammatory lesions with combination doxycycline 40 mg modified release capsules (DMR) and ivermectin 1% cream (IVM), compared to IVM plus placebo, in adults with severe papulopustular rosacea (IGA 4*) at 12 weeks. |
| 2018-06-02 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Doxycycline Hyclate Capsules USP zyduslife.com ↗
Zydus Cadila has received the final approval from the USFDA to market Doxycycline Hyclate Capsules USP, 50 mg and 100 mg. |
| 2018-05-07 | Galderma R&D | Results Galderma Announces Results of ALAMO: A Real-World, Phase 4 Study Demonstrating Efficacy and Safety of Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% Plus Oral Doxycycline 200 mg in Treating Severe Inflammatory Acne galderma.com ↗
In this study, the primary efficacy endpoint of reduction in number of inflammatory lesions at the end of the 12-week treatment period was met. |
| 2017-09-20 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Doxycycline Tablets USP zyduslife.com ↗ |
| 2011-02-18 | Impax Laboratories, LLC | Regulatory Impax Laboratories Receives Final FDA Approval for Generic Adoxa(R) 150 mg Capsules amneal.com ↗
HAYWARD, Calif., Feb 18, 2011 (BUSINESS WIRE) -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application for its generic version of Adoxa(R) (doxycyline monohydrate, 150 mg capsules). |
| 2010-12-29 | Impax Laboratories, LLC | Regulatory Impax Laboratories Receives Final FDA Approval for Generic Doryx(R) 75 and 100mg Tablets amneal.com ↗
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application for the generic version of Doryx(R) (doxycyline hyclate delayed-release) 75 and 100mg tablets. |
| 2010-11-29 | Galderma R&D | Results Galderma announces Results of largest-ever Rosacea Trial galderma.com ↗
In the ORCA study, results found that the side effect profile of Oracea®, even in large populations, was consistent with that seen in controlled, clinical trials, with the most frequently reported side effects being mild to moderate nausea and diarrhea. |
| 2009-09-21 | Impax Laboratories, LLC | Regulatory Impax Laboratories Confirms Patent Challenge Relating to ORACEA(R) Delayed-Release Capsules, 40mg amneal.com ↗
Impax filed its Abbreviated New Drug Application (“ANDA”) containing a paragraph IV certification for a generic version of ORACEA® with the U.S. Food & Drug Administration (“FDA”). |
| 2009-03-17 | Impax Laboratories, LLC | Regulatory Impax Confirms ANDA Filing for Doryx(R) Tablets 150 mg amneal.com ↗
Impax's ANDA, contains a Paragraph IV certification stating that the Company believes its product does not infringe US Patent No. 6,958,161, or that the patent is invalid or unenforceable. |
| 2007-11-12 | Lannett Company, Inc. | Regulatory LANNETT COMPANY RECEIVES FDA APPROVALS FOR DOXYCYCLINE TABLETS, 75 MG AND 150 MGPDF Version investorroom.com ↗ |
All press releases naming this drug 45 releases
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 392 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doxycycline | “Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to...” NCT01730352 ↗370“Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher,...” NCT00332163 ↗ “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗ “Based on the susceptibility results and penicillin-allergic test, a tailored 7-day triple or quadruple therapy regimen is prescribed, including Tegoprazan , Amoxicillin,...” NCT07405697 ↗ “patients will receive LOAD therapy comprising of levofloxacin (250 mg with breakfast), omeprazole (40 mg before breakfast), nitazoxanide (Alina) (500 mg twice daily with meals)...” NCT06050824 ↗ “This is a self-controlled single-site study of healthy subjects receiving an ablative fractional CO2 (carbon dioxide) laser procedure followed by topical application of...” NCT05411484 ↗ “Group3: (110) participants received Levofloxacin quadruple regimen (LOAD) in the form of nitazoxanide 500 mg bid, levofloxacin 250 mg QD, omeprazole 40 mg QD, and doxycycline...” NCT04039412 ↗ “Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and...” NCT00713999 ↗ “Doxycycline, a matrix metalloproteinase inhibitor, prevented matrix metalloproteinase-2-induced troponin I cleavage in rat hearts and improved contractile function following...” PMID 23928836 ↗ Nov 2013 “Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours...” NCT06188442 ↗ “per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a...” NCT04447625 ↗ |
| Known as | Adoxa | “Mylan's doxycycline monohydrate 100 mg tablets to Par's Adoxa® 100 mg tablets” NCT00649571 ↗1“Adoxa Tablets 100 mg” NCT00648180 ↗ |
| Known as | ALTY-0501 | “ALTY-0501 (Doxycycline 0.025% Ophthalmic Solution)” NCT00439400 ↗ |
| Known as | Atridox 10% | “doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket” NCT05875506 ↗ |
| Known as | Bassado | “tablets of DOXY hydrocloride (Bassado)” NCT04846335 ↗ |
| Known as | CASnr 564-25-0 (doxycycline); 17086-28-1 (doxycycline monohydraat) | “CASnr 564-25-0 (doxycycline); 17086-28-1 (doxycycline monohydraat)” NCT01207739 ↗ |
| Known as | D-PLEX | “D-PLEX is a new formulation of extended controlled release Doxycycline.” NCT02731573 ↗ |
| Known as | Dexxon | “either doxycycline (Dexxon, in a dose of 200 mg the first day and then 100 mg per day for four days) or placebo after presumed exposure to TBRF” PMID 16837678 ↗ Jul 2006 |
| Known as | DOX | “Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug...” NCT04860505 ↗4“a single 1 g intravenous (IV) dose of ceftriaxone (CRO) plus doxycycline (DOX) versus a single 800 mg oral dose of cefixime (CFM) plus DOX for the treatment of NG-CT co-infection” PMID 35810277 ↗ Jul 2022 “Doxycycline (DOX) is an inexpensive, FDA approved antibiotic that inhibits MMPs and reduces nitric oxide synthesis.” NCT00064766 ↗ “Doxycycline (DOX) has been proven in vitro to inhibit MMP-mediated degradation of stromal matrix.” PMID 22325113 ↗ Feb 2012 “Doxycycline (DOX) is a potent MMP inhibitor.” NCT01375491 ↗ |
| Known as | Doxy | “doxycycline (Doxy) disrupts amyloid fibrils in vitro and in animal models synergistically with tauroursodeoxycholic acid (TUDCA).” NCT03481972 ↗ |
| Known as | Doxybene | “doxycycline (Doxybene) 200mg” NCT06710600 ↗ |
| Known as | Doxycap. Registration No: MAL 19921000A | “Doxycap. Registration No: MAL 19921000A” NCT04234945 ↗ |
| Known as | Doxycyclin | “Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin” NCT03491995 ↗7“•Doxycyclin, amoxicillin and metronidazole” NCT02345733 ↗ “Doxycyclin, amoxicillin and metronidazole” NCT02217722 ↗ “* Doxycyclin : 200mg/day” NCT05074147 ↗ |
| Known as | Doxycycline Anhydrous | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03457636 ↗ |
| Known as | Doxycycline Capsule | “Drug: Doxycycline Capsule” NCT06069141 ↗ |
| Known as | Doxycycline Hcl | “Drug: Doxycycline Hcl” NCT04846335 ↗ |
| Known as | doxycycline hyclate | “Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of...” NCT03608774 ↗12“doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket” NCT05875506 ↗ “All eligible subjects will receive doxycycline hyclate (100 mg twice daily) as well as TUDCA 250 mg three times a day orally.” NCT01855360 ↗ “Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years” NCT00066027 ↗ “doxycycline PEP (doxycycline hyclate, 200 mg taken within 72 hours after condomless sex)” PMID 38118022 ↗ Dec 2023 “Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.” NCT00688064 ↗ “One 200 mg doxycycline hyclate delayed release (DR) tablet” NCT07755618 ↗ “Doxycycline Hyclate capsules, USP 50 mg” NCT04504123 ↗ “doxycycline hyclate 20 mg twice daily” NCT00041977 ↗ “Doxycycline hyclate (Doryx)” NCT00635609 ↗ “Drug: Doxycycline Hyclate” NCT04762134 ↗ |
| Known as | doxycycline hydrochloride | “11After hysteroscopic diagnosis of chronic endometritis, patients received monotherapy with doxycycline hydrochloride capsules for 14 days.” NCT07180563 ↗ |
| Known as | doxycycline monohydrate | “Nanodox 1% (doxycycline monohydrate hydrogel)” NCT02910011 ↗8“NanoDOX 1% doxycycline monohydrate Hydrogel” NCT01547325 ↗ “Doxycycline Monohydrate Tablets (100 mg” NCT00649571 ↗ “Doxycycline Monohydrate Tablets 100 mg” NCT00648180 ↗ |
| Known as | Doxycycline Monohydrate USP | “NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser” NCT05411484 ↗ |
| Known as | Doxycycline Sandoz | “(Doxycycline Sandoz 100 mg), 100mg/day during 3 months followed by placebo during 3 months” NCT03334682 ↗ |
| Known as | Doxycycline Tablets | “Drug: Doxycycline Tablets” NCT03194204 ↗ |
| Known as | Doxycycline-Doxylin | “Doxycycline-Doxylin®” NCT02033408 ↗ |
| Known as | Nanodox | “Nanodox 1% (doxycycline monohydrate hydrogel)” NCT02910011 ↗1“NanoDOX 1% doxycycline monohydrate Hydrogel” NCT01547325 ↗ |
| Known as | Oracea | “ORACEA® (40mg doxycycline) capsule daily for 24 months” NCT01782989 ↗ |
| Known as | Oraycea | “Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.” NCT03340961 ↗ |
| Known as | Periostat | “The purpose of this study is to determine whether doxycycline (Periostat) at a sub-antimicrobial dose will decrease reperfusion injury after coronary artery bypass grafting...” NCT00246740 ↗ |
| Known as | Periostat(R) | “The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg Tablets, taken twice daily is effective in reducing the red and white heads and...” NCT00041977 ↗ |
| Known as | tetracycline | “doxycycline (tetracycline)” NCT07320001 ↗ |
| Known as | Vibramycin | “Evaluate the clinical efficacy and safety of WC2031 200 mg tablets taken orally once a day for 7 days versus Vibramycin (doxycycline) 100 mg capsules taken orally twice a day for 7 days” NCT01113931 ↗1“Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt)” NCT03533231 ↗ |
| Known as | Zadorin-100 (doxycycline), licence number Swissmedic: 43051 | “Zadorin-100® (doxycycline), licence number Swissmedic: 43051” NCT01879930 ↗ |
| Action | Inhibit | “inhibits MMPs” NCT00064766 ↗ |
| Modality | Small molecule | “These drugs, which are tetracycline derivatives, can reduce the levels of a family of enzymes, called matrix metalloproteases” NCT00243893 ↗ |
| Route | Oral | “Doxycycline HCI 10mg po for 2 weeks” NCT00012688 ↗ |
| Target | MMP9 | “MMP-9 inhibiting properties” NCT00538967 ↗ |